After J.P. Morgan and BMO Capital gave Eli Lilly & Co (NYSE: LLY) a Buy rating last month, the company received another Buy, this time from Mizuho Securities. Analyst Vamil Divan reiterated a Buy rating on Eli Lilly & Co yesterday and set a price target of $356.00. The company’s shares closed last Monday at $291.28.
According to TipRanks.com, Divan is a 1-star analyst with an average return of -2.5% and a 45.6% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and ACADIA Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Eli Lilly & Co with a $324.64 average price target, implying an 11.8% upside from current levels. In a report issued on May 31, SVB Securities also reiterated a Buy rating on the stock.
Eli Lilly & Co’s market cap is currently $276.8B and has a P/E ratio of 43.20.
Based on the recent corporate insider activity of 135 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LLY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1876, Eli Lilly & Co. is a leading healthcare company that manufactures and sells pharmaceutical products worldwide. The company is headquartered in Indianapolis, Indiana.
Read More on LLY: